NCT07335341 Case-Specific Health Care Professional Clinical Survey of Liberant™ Thrombectomy System
| NCT ID | NCT07335341 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Medtronic Endovascular |
| Condition | Venous Embolism of Lower Extremities (Diagnosis) |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2026-02-24 |
| Primary Completion | 2026-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2026-02-24 with a primary completion date of 2026-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of Case-Specific Health Care Professional (HCP) Clinical Survey of Liberant™ Thrombectomy System, also known as the Liberant Clinical Assessment, is to collect first-in-human clinical data to confirm the safety and performance of the Medtronic Liberant™ thrombectomy system when used for the removal of fresh, soft emboli or thrombi from the vessels of the peripheral arterial and venous systems
Eligibility Criteria
Patient case selection to be included in the clinical assessment will be specific to Liberant and will be made according to the following criteria: 1. Patient treated is age ≥ 22 years at the time of procedure 2. Use of Liberant in accordance with the device labeling within 72 hours of index procedure
Contact & Investigator
John R Laird Jr, MD
PRINCIPAL INVESTIGATOR
Medtronic Endovascular
Frequently Asked Questions
Who can join the NCT07335341 clinical trial?
This trial is open to participants of all sexes, aged 22 Years or older, studying Venous Embolism of Lower Extremities (Diagnosis). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07335341 currently recruiting?
Yes, NCT07335341 is actively recruiting participants. Contact the research team at manasa.gudipally@medtronic.com for enrollment information.
Where is the NCT07335341 trial being conducted?
This trial is being conducted at Washington D.C., United States, Naples, United States, New York, United States, Plano, United States.
Who is sponsoring the NCT07335341 clinical trial?
NCT07335341 is sponsored by Medtronic Endovascular. The principal investigator is John R Laird Jr, MD at Medtronic Endovascular. The trial plans to enroll 50 participants.